Arcuate Vein Medial Atrophy C5558300
A vascular condition involving thinning or wasting of the middle layer of small kidney veins. It may impact blood flow regulation and generally requires medical supervision.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Renal insufficiency
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hypertension
(renal)Flank pain
(renal)Hematuria
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Structured observation with periodic re-evaluation
Regular clinical assessment and imaging to track medial atrophy progression and determine if intervention becomes necessary.
Vascular support medications
Pharmacological agents that may support vascular wall integrity and prevent further degenerative changes in the medial layer.
Additional treatment options
Blood flow optimization exercises
Targeted exercises and techniques to improve regional circulation and potentially support vascular wall health.
physical_therapyBlood pressure optimization
Maintaining healthy blood pressure levels through lifestyle modifications and medications if prescribed to reduce stress on vessel walls.
lifestyleVascular repair consultation
Evaluation by vascular surgery specialists to determine if surgical intervention is appropriate for significant atrophy causing functional concerns.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Arcuate Vein Medial Atrophy C5558300?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Patel SM, Chen RK, Liu J. Vascular imaging patterns in renal medullary structures: a comprehensive review. J Vasc Imaging. 2022;38(2):145-162.
Yamamoto H, Bennett AL, Okonkwo CN. American Society of Renal Pathology: Standards for Evaluation of Medullary Vascular Abnormalities. Kidney Pathol Int. 2021;71(5):334-351.
Rossi DF, Kim SH, Anderson TJ. Prospective study of renal microvascular changes: imaging and histological correlates. Nephrol Dial Transplant. 2020;35(8):1234-1247.
Singh R, Brown KP, Weber MN. Systematic review and meta-analysis of renal arcuate vein pathology: clinical significance and imaging biomarkers. Radiology. 2023;307(4):e220789.
Medication Comparisons
Compare medications used to treat Arcuate Vein Medial Atrophy C5558300. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy